Patents by Inventor Louise Scharf
Louise Scharf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240132582Abstract: The present disclosure provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human IL-36 cytokines, IL-36?, IL-36?, and/or IL-36?, and block the IL-36 stimulated signaling pathways. Compositions comprising such binding proteins and methods of making and using such binding proteins are also provided.Type: ApplicationFiled: December 13, 2023Publication date: April 25, 2024Applicant: 23andMe, Inc.Inventors: Chingwei Vivian Lee, Germaine Fuh-Kelly, Louise Scharf, Tina Thai, Ashka Bharat Patel, Shashank Bharill, Erik Edward Karrer
-
Patent number: 11897940Abstract: This invention relates to broadly neutralizing and potent anti-HIV-1 antibodies, kits, and methods of use thereof.Type: GrantFiled: March 30, 2022Date of Patent: February 13, 2024Assignees: THE ROCKEFELLER UNIVERSITY, CALIFORNIA INSTITUTE OF TECHNOLOGYInventors: Michel Nussenzweig, Natalia T. Freund, Pamela J. Bjorkman, Louise Scharf
-
Patent number: 11884719Abstract: The present invention provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human IL-36 cytokines, IL-36?, IL-36?, and/or IL-36?, and block the IL-36 stimulated signaling pathways. Compositions comprising such binding proteins and methods of making and using such binding proteins are also provided.Type: GrantFiled: December 19, 2019Date of Patent: January 30, 2024Assignee: 23andMe, Inc.Inventors: Chingwei Vivian Lee, Germaine Fuh-Kelly, Louise Scharf, Tina Thai, Ashka Bharat Patel, Shashank Bharill, Erik Edward Karrer
-
Publication number: 20240018239Abstract: The present disclosure provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human CD200R1 receptor protein (hu-CD200R1) and are capable of decreasing, inhibiting, and/or fully-blocking immune regulatory effects mediated by hu-CD200R1. The present disclosure also provides methods of using the antibodies (and compositions thereof) to treat diseases and conditions responsive to decreasing, inhibiting and/or blocking immune regulatory function or activity mediated by CD200 binding to CD200R1.Type: ApplicationFiled: August 24, 2023Publication date: January 18, 2024Applicant: 23andMe, Inc.Inventors: Yu CHEN, Jilean Beth FENAUX, Germaine FUH-KELLY, Yao-Ming HUANG, Wei-Jen CHUNG, Erik KARRER, Cecilia LAY, Steven J. PITTS, Louise SCHARF
-
Patent number: 11787861Abstract: The present disclosure provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human CD200R1 receptor protein (hu-CD200R1) and are capable of decreasing, inhibiting, and/or fully-blocking immune regulatory effects mediated by hu-CD200R1. The present disclosure also provides methods of using the antibodies (and compositions thereof) to treat diseases and conditions responsive to decreasing, inhibiting and/or blocking immune regulatory function or activity mediated by CD200 binding to CD200R1.Type: GrantFiled: May 28, 2021Date of Patent: October 17, 2023Assignee: 23andMe, Inc.Inventors: Yu Chen, Jilean Beth Fenaux, Germaine Fuh-Kelly, Yao-Ming Huang, Wei-Jen Chung, Erik Edward Karrer, Cecilia Lay, Steven J. Pitts, Louise Scharf
-
Publication number: 20230279082Abstract: The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.Type: ApplicationFiled: April 7, 2023Publication date: September 7, 2023Applicants: The Rockefeller University, California Institute of TechnologyInventors: Hugo Mouquet, Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf
-
Publication number: 20230183343Abstract: The present disclosure provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human CD96 receptor protein (hu-CD96) and are capable of decreasing, inhibiting, and/or fully-blocking immune regulatory effects mediated by hu-CD96. The present disclosure also provides methods of using the antibodies (and compositions thereof) to treat diseases and conditions responsive to decreasing, inhibiting and/or blocking immune regulatory function or activity mediated by CD96 binding to CD155, including effects arising from CD96 interactions with CD226 and/or TIGIT.Type: ApplicationFiled: November 18, 2022Publication date: June 15, 2023Applicant: 23andMe, Inc.Inventors: Yu CHEN, Chingwei Vivian LEE, Germaine FUH-KELLY, Zuoan YI, Yao-ming HUANG, Valentine YEUNG, Krista Maureen MCCUTCHEON, Samuel NALLE, Augusta Eleanor BROUGHTON, Louise SCHARF, Navneet SINGH, Tina THAI, Shouhua XIAO
-
Patent number: 11649276Abstract: The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.Type: GrantFiled: September 9, 2021Date of Patent: May 16, 2023Assignees: The Rockefeller University, California Institute of TechnologyInventors: Hugo Mouquet, Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf
-
Patent number: 11555073Abstract: The present disclosure provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human CD96 receptor protein (hu-CD96) and are capable of decreasing, inhibiting, and/or fully-blocking immune regulatory effects mediated by hu-CD96. The present disclosure also provides methods of using the antibodies (and compositions thereof) to treat diseases and conditions responsive to decreasing, inhibiting and/or blocking immune regulatory function or activity mediated by CD96 binding to CD155, including effects arising from CD96 interactions with CD226 and/or TIGIT.Type: GrantFiled: December 18, 2019Date of Patent: January 17, 2023Assignee: 23andMe, Inc.Inventors: Yu Chen, Chingwei Vivian Lee, Germaine Fuh-Kelly, Zuoan Yi, Yao-ming Huang, Valentine Yeung, Krista Maureen McCutcheon, Samuel Nalle, Augusta Eleanor Broughton, Louise Scharf, Navneet Singh, Tina Thai, Shouhua Xiao
-
Publication number: 20220348642Abstract: This invention relates to broadly neutralizing and potent anti-HIV-1 antibodies, kits, and methods of use thereof.Type: ApplicationFiled: March 30, 2022Publication date: November 3, 2022Applicants: The Rockefeller University, California Institute of TechnologyInventors: Michel Nussenzweig, Natalia T. Freund, Pamela J. Bjorkman, Louise Scharf
-
Patent number: 11325966Abstract: This invention relates to broadly neutralizing and potent anti-HIV-1 antibodies, kits, and methods of use thereof.Type: GrantFiled: December 22, 2017Date of Patent: May 10, 2022Assignees: The Rockefeller University, California Institute of TechnologyInventors: Michel Nussenzweig, Natalia T. Freund, Pamela J. Bjorkman, Louise Scharf
-
Publication number: 20220002390Abstract: The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.Type: ApplicationFiled: September 9, 2021Publication date: January 6, 2022Applicants: The Rockefeller University, California Institute of TechnologyInventors: Hugo Mouquet, Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf
-
Publication number: 20220002391Abstract: The present invention relates to broadly neutralizing anti-HIV-1 antibodies and isolated antigens. Also disclosed are related methods and compositions.Type: ApplicationFiled: September 10, 2021Publication date: January 6, 2022Applicants: The Rockefeller University, California Institute of TechnologyInventors: Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf, Johannes Scheid
-
Publication number: 20210371521Abstract: The present disclosure provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human CD200R1 receptor protein (hu-CD200R1) and are capable of decreasing, inhibiting, and/or fully-blocking immune regulatory effects mediated by hu-CD200R1. The present disclosure also provides methods of using the antibodies (and compositions thereof) to treat diseases and conditions responsive to decreasing, inhibiting and/or blocking immune regulatory function or activity mediated by CD200 binding to CD200R1.Type: ApplicationFiled: May 28, 2021Publication date: December 2, 2021Applicant: 23andMe, Inc.Inventors: Yu CHEN, Jilean Beth FENAUX, Germaine FUH-KELLY, Yao-Ming HUANG, Wei-Jen CHUNG, Erik Edward KARRER, Cecilia LAY, Steven J. PITTS, Louise SCHARF
-
Patent number: 11155605Abstract: The present invention relates to broadly neutralizing anti-HIV-1 antibodies and isolated antigens. Also disclosed are related methods and compositions.Type: GrantFiled: September 23, 2019Date of Patent: October 26, 2021Assignees: THE ROCKEFELLER UNIVERSITY, CALIFORNIA INSTITUTE OF TECHNOLOGYInventors: Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf, Johannes Scheid
-
Patent number: 11142564Abstract: The present invention relates to anti-HW antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immuno suppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.Type: GrantFiled: July 10, 2019Date of Patent: October 12, 2021Assignees: THE ROCKEFELLER UNIVERSITY, CALIFORNIA INSTITUTE OF TECHNOLOGYInventors: Hugo Mouquet, Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf
-
Publication number: 20200199203Abstract: This invention relates to broadly neutralizing and potent anti-HIV-1 antibodies, kits, and methods of use thereof.Type: ApplicationFiled: December 22, 2017Publication date: June 25, 2020Inventors: Michel Nussenzweig, Natalia T. Freund, Pamela J. Bjorkman, Louise Scharf
-
Publication number: 20200199217Abstract: The present disclosure provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human IL-36 cytokines, IL-36?, IL-36?, and/or IL-36?, and block the IL-36 stimulated signaling pathways. Compositions comprising such binding proteins and methods of making and using such binding proteins are also provided.Type: ApplicationFiled: December 19, 2019Publication date: June 25, 2020Applicant: 23andMe, Inc.Inventors: Chingwei Vivian LEE, Germaine FUH-KELLY, Louise SCHARF, Tina THAI, Ashka Bharat PATEL, Shashank BHARILL, Erik Edward KARRER
-
Publication number: 20200199227Abstract: The present disclosure provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human CD96 receptor protein (hu-CD96) and are capable of decreasing, inhibiting, and/or fully-blocking immune regulatory effects mediated by hu-CD96. The present disclosure also provides methods of using the antibodies (and compositions thereof) to treat diseases and conditions responsive to decreasing, inhibiting and/or blocking immune regulatory function or activity mediated by CD96 binding to CD155, including effects arising from CD96 interactions with CD226 and/or TIGIT.Type: ApplicationFiled: December 18, 2019Publication date: June 25, 2020Applicant: 23andMe, Inc.Inventors: Yu CHEN, Chingwei Vivian LEE, Germaine FUH-KELLY, Zuoan YI, Yao-ming HUANG, Valentine YEUNG, Krista Maureen MCCUTCHEON, Samuel NALLE, Augusta Eleanor BROUGHTON, Louise SCHARF, Navneet SINGH, Tina THAI, Shouhua XIAO
-
Publication number: 20200140528Abstract: The present invention relates to broadly neutralizing anti-HIV-1 antibodies and isolated antigens. Also disclosed are related methods and compositions.Type: ApplicationFiled: September 23, 2019Publication date: May 7, 2020Applicant: The Rockefeller UniversityInventors: Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf, Johannes Scheid